CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis

Liat Shargian*, Pia Raanani, Moshe Yeshurun, Anat Gafter-Gvili, Ronit Gurion

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
JournalBritish Journal of Haematology
StateAccepted/In press - 2022


  • B-cell
  • CAR-T
  • CD19
  • chimaeric antigen receptor
  • diffuse large cell
  • lymphoma
  • lymphoma
  • meta-analysis
  • refractory relapse

Cite this